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ABSTRACT 
Background: The prevalence and severity of duodenal injury in coeliac disease patients controlled on 
a gluten-free diet is unclear.
Aims: To use quantitative histology to assess duodenal injury in treated coeliac disease.
Methods: Quantitative histology in pre-treatment duodenal biopsies collected in clinical trials 
assessing an investigational immunotherapy for coeliac disease were analysed. Morphometric 
readings were converted to Marsh classifications. 
Results: 93 patients had duodenal biopsies. For well-oriented sections of second part biopsies, six 
(6%) patients were classified as Marsh 0 or 1, 30 (33%) as Marsh 2, and 56 (60%) as Marsh 3a or 3b. 
In second part biopsies from 78 seronegative patients on gluten-free diet >2 years, 27 (35%) were 
Marsh 2 and 45 (58%) were Marsh 3a or 3b. Distal compared to proximal duodenal biopsies had 
significantly higher villus height to crypt depth ratios (median, third part: 2.1 versus bulb: 1.4; 
P<0.0001) and higher intraepithelial lymphocyte density (44 versus 30; P=0.0002). The sum of paired 
villus height and crypt depth measurements was correlated strongly with villus height (rs = 0.82, 
P<10-10). At least one biopsy was graded Marsh 3a or worse in all 26 patients who had serial biopsies 
from the bulb, first, second and third part, but was overlooked in 20 patients by subjective histology. 
Conclusions: Quantitative histology in well-oriented biopsy sections reveals villus atrophy in the 
majority of patients with coeliac disease who appear well-controlled on gluten-free diet. 
Standardisation of biopsy collection, processing and evaluation could substantially improve the value 
of follow-up biopsies in coeliac disease. 
Key words: Coeliac disease, transglutaminase IgA, serology, quantitative histology, gluten-free diet. 
Abbreviations: Human leukocyte antigen-DQ (HLA-DQ), transglutaminase 2 (TG2).
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INTRODUCTION
Persistent duodenal mucosal damage in patients with coeliac disease on gluten-free diet is associated 
with increased severe long-term complications (1). A recent meta-analysis found 31% of patients with 
coeliac disease had persistent villus atrophy on gluten-free diet, and only half of these patients had 
elevated transglutaminase 2 (TG2) IgA serology (2). A corollary of these findings is that about one in 
five patients apparently well controlled on gluten-free diet with normal TG2 serology has duodenal 
villus atrophy. These conclusions are, however, based on routine processing, and subjective or semi-
quantitative analysis of biopsies, usually from the distal duodenum.
Quantitative histology provides accurate assessment of duodenal mucosal injury in coeliac disease by 
using highly reproducible measurements of villous height, crypt depth and intra-epithelial density in 
well-oriented distal duodenal biopsies (3, 4). With implementation of rigorous standard operating 
procedures, quantitative duodenal histology outperforms conventional qualitative histology using 
grouped classifications such as Marsh score (5-7), and is emerging as a preferred measure of efficacy 
in therapeutics trials for coeliac disease (5, 8-10). Perhaps surprisingly, quantitative histology has not 
yet, to our knowledge, been used to evaluate disease activity/duodenal injury in patients who appear 
“well-controlled” coeliac disease and are in serological remission. 
Quantitative histology in baseline duodenal biopsies collected in phase 1 and 2 clinical trials assessing 
an investigational immunotherapy, Nexvax2®, for coeliac disease provided the opportunity to assess 
duodenal injury in patients with “well-controlled” coeliac disease on gluten-free diet (11-13).  The 
primary objective of this study was to use quantitative histology to assess duodenal mucosal injury in 
treated coeliac disease, and in particular those patients who are well established on gluten-free diet, 
and in serological remission.
METHODS
Study design
The study analysed quantitative histology of duodenal biopsies collected during the pre-treatment 
periods of four clinical trials testing a novel investigational immunotherapy (Nexvax2®).  Patients A
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were recruited at sites in Australia, New Zealand, and the United States. In each study, a subgroup of 
patients had biopsies collected as a safety assessment before and after the treatment period. Details of 
the four studies are summarized in Table 1. In the three phase 1 studies, which have been reported in 
detail elsewhere (11, 12), patients with coeliac disease were maintaining their usual gluten-free diet 
had no study interventions before their pre-treatment biopsy. In the phase 2 (“RESET CeD”) trial, 
which has also been described elsewhere (13), patients with coeliac disease were maintaining their 
usual gluten-free diet, but had a single bolus gluten challenge (6 grams of gluten protein taken as 10 
grams vital wheat gluten flour in water) three weeks before biopsy collection according to the 
protocol described by Tye-Din et al (14). 
Patients and interventions
All patients gave written, informed consent prior to undergoing any trial-related procedures. 
Eligibility criteria for each clinical trial have been reported fully elsewhere (11-13). In brief, for all 
four studies, patients who had biopsies collected had met initial screening criteria, which included 
being aged between 18 to 70 years, having documented duodenal villus atrophy while consuming 
gluten, being positive for HLA-DQA1*05 and DQB1*02 (“HLA DQ2.5”), and having maintained a 
gluten-free diet for at least one year. Patients with uncontrolled complications of celiac disease 
including refractory coeliac disease were excluded. In phase 1 studies, additional study-specific 
eligibility criteria were intended to select for patients entering the treatment period who were strictly 
maintaining a gluten-free diet. In the first and second phase 1 studies, patients who had a known 
gluten exposure within two months prior to screening were excluded, and patients were discontinued 
if subjective assessment of Marsh class for any pretreatment biopsy was more severe than 1 (raised 
intra-epithelial lymphocytes with normal villous architecture). In the third phase 1 study, patients 
were excluded if both TG2 IgA and deamidated gliadin peptide IgG serology were elevated, or if their 
score in the Celiac Dietary Adherence Test suggested non-compliance to gluten-free diet. In the phase 
2 study, patients in the biopsy subgroup had met the inclusion criteria that experienced worsening 
digestive symptoms on the day of screening gluten food challenge three weeks earlier.
Quantitative duodenal histologyA
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Biopsy collection, processing and quantitative histology methods in the first and second phase 1 
studies have been described in detail elsewhere (3, 11, 12). Briefly, biopsies were collected from four 
sites: the duodenal bulb, and from the first, second, and third parts of the duodenum. Two biopsies 
were obtained at each site with a single biopsy per pass of the forceps, and placed in formalin fixative. 
Both biopsies from each site were processed together; they were embedded in paraffin, sectioned, and 
stained with haemotoxylin and eosin, and by anti-CD3 immunochemistry. The pathologist at the 
central laboratory made a subjective assessment  of whether a patient had any biopsy consistent with a 
Marsh classification above 1. Subsequently the same histology slides as used to assess the initial 
Marsh score were batched and sent to the University of Tampere for quantitative histology. If sections 
from a biopsy were considered poorly oriented and prevented accurate assessment, the central 
pathology laboratory was requested to re-cut tissue sections. Two observers (JT, AP) analysed all 
slides independently and were unaware of the clinical data or laboratory findings of the patients. 
Replicate measurements of villus height, crypt depth and frequency of intraepithelial CD3+ 
lymphocytes per 100 villus enterocytes (IELs) with well-oriented villus-crypt units were determined 
according to published protocols (3). Final Marsh classifications for formalin-fixed biopsies were 
based on average villus height to crypt depth ratios according to the previously reported conversion 
scale: villus height to crypt depth ratio ≥2.8 for Marsh (M)0 if intraepithelial CD3+ lymphocyte 
density per 100 enterocytes <25, or M1 if ≥25; villus height to crypt depth ratio 2.0 - 2.7 for M2; 
villus height to crypt depth ratio 1.2 - 1.9 for M3a; villus height to crypt depth ratio 0.5 - 1.1 for M3b; 
and villus height to crypt depth ratio 0.0-0.4 for M3c (15). 
In the third phase 1 study and phase 2 study, biopsy collection was limited to the second part of the 
duodenum, PAXgene tissue fixative (QIAGEN, Hilden, Germany) was used, and biopsies were sent 
directly to Jilab Inc. (Tampere, Finland) for processing and quantitative histology.  Biopsy collection 
and handling, and the protocol for quantitative histology are described elsewhere (3, 12, 16). Paxgene 
fixative facilitated a wider repertoire of immunohistochemical, immunofluorescence assessments, and 
genome-wide transcriptome analysis in the same tissue sample (16). In brief, after collection, biopsies 
were placed one per compartment of a multi-compartment tissue cassette. The cassette was immersed 
in PAXgene fixative for 1-4 hours, and then transferred to the proprietary storage solution in A
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PAXgene dual-chamber fixative containers (Qiagen #765112, Venlo, Netherlands). Samples in 
fixative were shipped at ambient temperature and then stored at +4°C until processing. Each biopsy 
was embedded in a separate paraffin block under a dissection microscope and aimed for a cutting 
plane perpendicular to the mucosal lumen surface to orientate the specimens correctly. As for the 
earlier studies, the slides were stained with haematoxylin and eosin and by anti-CD3 
immunochemistry. De-identified slides were scanned as whole-slide images using a SlideStrider 
scanner at a resolution of 0.28 μm per pixel (Jilab Inc., Tampere, Finland). Images were stored as 
JPEG2000 files in the image server and viewed over the Internet with web-based client software 
developed for this study (Celiac Slide Analyzer). The same two observers (JT, AP) analysed all slides 
independently and were unaware of the clinical data or laboratory findings of the patients. Final 
Marsh classifications for PAXgene-fixed biopsies were based on average villus height to crypt depth 
ratios according to the previously reported conversion scale: villus height to crypt depth ratio ≥2.3 for 
Marsh (M)0 if intraepithelial CD3+ lymphocyte density per 100 enterocytes <25, or M1 if ≥25; villus 
height to crypt depth ratio 1.8 - 2.3 for M2; villus height to crypt depth ratio 1.1 - 1.7 for M3a; villus 
height to crypt depth ratio 0.5 - 1.0 for M3b; and villus height to crypt depth ratio 0.0-0.4 for M3c 
(16). 
Statistical analyses
No formal power calculation was undertaken for these exploratory, post hoc analyses. Non-parametric 
tests were used to assess the significance of differences in paired (Wilcoxon signed rank test) or 
unpaired (Mann-Whitney test) observations, and to assess correlations (Spearman’s coefficient). All 
statistical tests were 2-tailed. Summary and significance statistics were computed using Graphpad 
Prism V7.0d.
RESULTS
Patient characteristics
Table 1 shows the characteristics of the 93 patients who had pre-treatment duodenal biopsies collected 
across three phase 1 trials and one phase 2 study investigating Nexvax2 in patients with coeliac 
disease. Disposition of patients in the phase 1 studies who had biopsies has been reported previously, A
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(11, 12) and is shown in Figure S1 for patients in the phase 2 study. Patient characteristics were 
similar for the four studies. The median period since diagnosis of coeliac disease was six years. Three 
(4%) of the 85 patients who had serology evaluated had elevated levels of transglutaminase IgA. At 
screening, 30 (75%) patients in phase 1 studies and 48 (91%) patients in the phase 2 study had been 
diagnosed and managed with a gluten-free diet for at least two years, and were confirmed sero-
negative for TG2-specific IgA. 
Quantitative histology in second part duodenal biopsies
Overall, among all 93 patients assessed, Table 2 shows six (6%) had second part duodenal biopsies 
classified as Marsh class 0 or 1, 30 (33%) had Marsh 2, and 56 (60%) had Marsh 3a or 3b. The 
proportion of patients with second part duodenal histology graded as Marsh 3 was similar for each 
study. There were non-significant trends for Marsh 3a and 3b classification to be less prevalent in 
patients confirmed as seronegative for transglutaminase 2 IgA who had been diagnosed for at least 
two years (58%) compared to other patients (78%), and more prevalent in patients subjectively 
assessed during screening in phase 1 studies as having Marsh class worse than 1 (84%) than those 
subjectively assessed as Marsh 0 or 1 (68%). Table 3 shows that there was no difference in the 
distribution of Marsh grades between patients recruited in Australia, New Zealand, and the United 
States.
Proximal to distal changes in duodenal quantitative histology
For all 26 patients having pre-treatment biopsies in the first and second phase 1 Nexvax2 clinical 
trials, two biopsies were collected from each of the bulb, first, second and third part of the duodenum. 
Figure 1 shows there were no significant differences in quantitative histology between the bulb and 
first part, but there were differences in villus height to crypt depth ratio and intra-epithelial 
lymphocyte density between proximal and distal sites that were progressive and statistically 
significant. Median villus height to crypt depth ratio increased from 1.4 (Marsh 3a) in the bulb to 2.1 
(Marsh 2) in the third part, and median intra-epithelial lymphocyte density increased modestly from 
30 in the bulb to 44 in the third part (normal <25). Intra-epithelial lymphocyte density in second part 
biopsies was significantly correlated with the bulb (Spearman rs = 0.70, P = 0.0001), first part (rs = A
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0.66, P = 0.0003) and third part (rs = 0.76, P < 0.0001) in the same patient. Villous height to crypt 
depth ratio in second part biopsies was significantly correlated with the first part (rs = 0.35, P = 0.044) 
and third part (rs = 0.41, P = 0.021) in the same patient. 
Quantitative histology identifies mucosal injury overlooked by subjective assessment 
It is well known that most small bowel mucosal biopsies are currently processed without orientation 
in the endoscopy or pathology laboratory, and that poor orientation may compromise interpretation of 
villus-crypt architecture (17). In PAXgene fixed biopsies in the present study, Marsh class changed 
with level of cutting in the same biopsy block, as presented in Figure 2. For example, the section 
shown in Figure 2A was classified as Marsh 1 (tall villi and increased intra-epithelial lymphocytes) 
becomes a crypt hyperplastic lesion classified as Marsh 3a in Figure 2F, and Figure 2C shows to the 
right, where the cutting is perpendicular to the luminal surface, a crypt hyperplastic lesion classified 
as Marsh 3c. When measuring all readable villus-crypt units in the six histology sections presented, 
the global mean villus height to crypt depth ratio is 0.85, i.e. Marsh class 3b according to Taavela et al (16). Hence, to improve orientation of tissue sections prepared by the central laboratory and allow 
accurate assessment by quantitative histology, 40% of biopsies from the first and second phase 1 
studies were re-cut. Overall, 26 (100%) patients had biopsies from at least one location graded as 
Marsh class 3a, 3b, or 3c (median 3b) by quantitative histology, which contrasted with the subjective 
assessment during screening that 20 (77%) had duodenal histology no worse than Marsh 1.
Villus height is linked to variability in duodenal villus-crypt length
The height of the villus-crypt axis (i.e. the sum of villus height and crypt depth) has been depicted as 
a constant, which implies that there is a reciprocal relationship between villus height and crypt depth 
(4). Figure 3 shows the relationships between measurements of duodenal villus height and crypt 
depth, and their ratio or sum for the pooled set of 169 biopsy assessments from 93 patients. As 
expected, villus height and crypt depth are significantly, but rather weakly correlated (Figure 3A), and 
that the sum of paired values of villus height and crypt depth are relatively constant with a median of 
533 μm (interquartile range: 482.5 - 575.5) (Figure 3B). The ratio between villus height and crypt 
depth is, as expected, correlated strongly positively with villus height (Spearman rs = 0.78, P <10-10), A
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and negatively with crypt depth (rs = 0.74, P <10-10) (Figure 3C). However, villus height increases 
about four-times more rapidly than crypt depth decreases as the sum of villus height and crypt depth 
increases (Figure 3D), and the sum of villus height and crypt depth is correlated strongly positively 
with villus height (rs = 0.82, P <10-10) and weakly negatively, but significantly, with crypt depth (rs = -
0.22, P = 0.004). When analysed separately, the correlation between the sum of villus height and crypt 
depth and villus height was statistically significant for each study and for each region of the 
duodenum (Table S1). Collectively, these findings provide support for a model of mucosal behavior, 
healing and deterioration that involves not just reciprocal changes in villus height and crypt depth, but 
also includes increasing villus-crypt length as villus height increases in patients with coeliac disease 
on gluten-free diet (Figure 4). 
DISCUSSION
This study used quantitative histology to assess duodenal mucosal injury in 93 patients with treated 
coeliac disease who enrolled in clinical trials of an investigational immunotherapy. Eligibility criteria 
for these clinical trials were intended to select for patients who were well-controlled on gluten-free 
diet, and consequently, transglutaminase IgA serology was elevated in fewer than 5% of participants 
tested. Altogether, quantitative histology of biopsies from the second part of the duodenum indicated 
mucosal “healing” (Marsh 0) in only one case, mucosal recovery (Marsh 0 – 2) in 36 (38%), and 
persistent villus atrophy (Marsh 3a, 3b or 3c) in 57 (61%) cases. Mucosal recovery (42%) and 
persistent villus atrophy (58%) were similar for the subgroup of 78 (84%) patients we defined as 
“well-controlled”, who were sero-negative for transglutaminase antibodies and had been established 
on gluten-free diet for at least two years. Severity of mucosal injury was similar across the three 
countries where patients were recruited, Australia, New Zealand and the United States. Persistent 
villus atrophy revealed by quantitative histology in our cohort of  “well-controlled” patients is, in fact, 
higher than the 38% recently reported for 1,345 patients with self-reported moderate or severe coeliac 
disease-associated symptoms (4). Even though it is well-known that persistent duodenal villus atrophy 
is not efficiently detected by transglutaminase serology in patients on gluten-free diet (2), our findings 
suggest that standard processing and subjective evaluation of duodenal biopsies also fails to detect A
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villus atrophy in many patients with treated coeliac disease. For example, in the first phase 1 study of 
Nexvax2 immunotherapy, subjective histology identified 14 of 16 patients as Marsh 0 or 1, but all 16 
had Marsh 3 lesions in at least one biopsy collected from four sites across the duodenum. Inadequate 
orientation of tissue sections and simply evaluating biopsies bases on villi only where sections show 
no crypts cut longitudinally appeared to contribute to unrecognized mucosal injury in our study, and 
has been highlighted in recent pathology guidelines (17). A novel aspect of our study was to assess 
quantitative histology at four duodenal sites from the bulb to third part. Villus flattening was 
significantly more severe in the proximal duodenum, but intraepithelial lymphocyte density was 
modestly higher in the distal duodenum. An unexpected finding was that the combined length of the 
duodenal villus-crypt unit can vary by as much as 50%, and this can be attributed to relative increases 
in villus height being four times as much as decreases crypt depth. These findings provide support for 
a model of mucosal behavior, healing and deterioration that involves not just reciprocal changes in 
villus height and crypt depth, but also includes increasing villus-crypt length as villus height increases 
in patients with coeliac disease on gluten-free diet (Figure 4).
Our study had several limitations. Biopsies evaluated were from patients in subgroups of those 
enrolled in four clinical trials testing an experimental immunotherapy. These patients may not be 
representative of randomly selected patients in Australia, New Zealand, or the United States because 
the eligibility criteria were intended to ensure only patients well-controlled on gluten-free diet were 
enrolled. Notably, the prevalence of elevated transglutaminase IgA serology in our study patients was 
similar to that reported in recent follow-up studies from Norway, Finland and Australia that reported 
persistent villus atrophy in 4% to 15% of adults on gluten-free diet for more than five years (18-20). 
Although the patients in phase 1 studies had no per protocol gluten exposure before collection of 
biopsies, those in the phase 2 study had consumed a bolus of six grams of gluten three weeks before 
biopsy collection. Consequently, biopsies in the phase 2 study may have shown residual effects of this 
gluten exposure, even though Marsh classes in these patients were similar to milder than those from 
phase 1 study patients. Although an important practical consideration for future studies, this study did 
not systematically compare evaluation of mucosal injury by the local pathologist with subsequent 
quantitative histology. Under-reporting the severity of mucosal injury in follow-up biopsies is A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
concerning for patients and treating physicians, but in this study was rectified by re-cutting biopsies 
with poorly orientated tissue sections. A further limitation of our findings might be that we did not 
consider potential drug-induced enteropathy to occur in our study subjects, for example subjects using 
Olmesartan (21), proton pump inhibitors, non-steroidal anti-inflammatory drugs or selective serotonin 
reuptake inhibitors (22).
This study had four principal findings. We confirm that quantitative histology demonstrates persistent 
duodenal mucosal injury in the majority of patients with coeliac disease on gluten-free diet (4), and 
extend this observation to patients who are sero-negative and would be considered “well-controlled”. 
Second, villus height to crypt depth ratio, and intra-epithelial lymphocytosis increase progressively 
from the proximal to distal duodenum. This finding highlights the importance of standardizing 
anatomical sites where biopsies are collected during clinical follow-up and in clinical trials. Third, 
there is a strong positive correlation between villus height and overall crypt-villus length, which may 
provide additional information regarding healing of the mucosa. Finally, there is a marked 
discrepancy between subjective histology and quantitative histology when evaluating duodenal 
mucosal injury in patients on gluten-free diet. While quantitative histology is unlikely to be practical 
in routine laboratory assessment of duodenal biopsies, our findings suggest that the clinical value of 
follow-up histology could be improved by adhering to published guidelines (17), which could more 
accurately reveal previously unrecognised mucosal injury in patients with coeliac disease on gluten-
free diet.
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Figure Legends
Figure 1. A shows villous height to crypt depth ratios, and B shows intraepithelial lymphocyte (IEL) 
densities in formalin-fixed biopsies from the proximal and distal duodenum. Two biopsies were 
collected from the bulb, 1st, 2nd and 3rd part of the duodenum in 26 patients enrolled in the first and 
second phase 1 studies of Nexvax2. Medians and interquartile ranges are shown; p values by 
Wilcoxon test. Data for biopsies with well-oriented villus-crypt units is shown; data for biopsies from 
the bulb for two patients are missing as neither had any well-oriented villus-crypt units observed.
Figure 2: A-F a series of hematoxylin eosin-stained cuttings of the same endoscopy forceps biopsy 
specimen fixed in PAXgene and embedded in paraffin. A shows the cutting that was graded as Marsh 
1 because of tall normal looking villi and an increased density of intraepithelial lymphocytes. The 
hallmark for tangential cutting is evident, no crypts are cut longitudinally, only cross sections of 
crypts are seen. Morphometry cannot be performed, and neither can a Marsh class can be given. B 
shows a section from the same biopsy block re-cut after tilting. C-F show four further sections 
resulting from further tilting between each re-cut. Crypt hyperplasia is evident and measurable villus-
crypt units in the 6 sections give a global mean villus height crypt depth ratio of 0.85, i.e Marsh class 
3b according to Taavela et al (16) 
Figure 3. Relationship between measurements of duodenal villus height and crypt depth, and their 
ratio or sum for the pooled set of 169 biopsy assessments from 93 patients. A shows villus height and 
crypt depth are significantly, but weakly correlated, (Spearman correlation coefficient and associated 
P-value). B shows the individual sums of paired values of villus height and crypt depth measurements 
in each clinical trial for each site sampled. The median (interquartile range) for all 169 samples was 
533 μm (482.5 - 575.5). No significant differences were found between biopsies from the 2nd part 
compared to biopsies from other sites in Study 1 and 2 (formalin-fixed), or 2nd part biopsies in Study 
3 and 4 (PAXgene-fixed). C shows the expected strong correlations between villus height to crypt 
depth ratio and villus height, and to crypt depth. D shows villus height increases more about four-
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times more rapidly than crypt depth decreases as the sum of villus height and crypt depth increases 
(VH+CrD = 0.81*VH+273, and CrD = -019*VH+273).
Figure 4. Schematic representation of the relationship between villus height and crypt depth 
measurements in the duodenal mucosa of patients with treated coeliac disease in the present study.
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Table 1. Study details and patient characteristics
Study: 1 2 3 4 Total
Study details
Nexvax2 trial 1st Phase 1 2nd Phase 1 3rd Phase 1 Phase 2
Biopsy locations in duodenum Bulb, 1st-3rd Bulb, 1st-3rd 2nd 2nd 
Biopsies per site 2 2 4 6
Start date 8Apr13 17Apr14 4Jan16 7Sept18
End date 10Sept13 31Jul14 20Sept16 25Mar19
Patient characteristics, number (%) of patients unless indicated
Number of patients having biopsies 16 10 14 53 93
Females 12 (75) 7 (70) 7 (50) 40 (75) 66 (71)
Age, years † 44 (33-57) 40 (25-55) 44 (33-57) 39 (33-51) 40 (32-51)
Years after diagnosis CeD † 6 (5-7) 3 (2-7) 6 (3-10) 7 (4-11) 6 (3-11)
<2 y after diagnosis CeD 1 (6) 0 1 (7) 3 (6) 5 (5)
2 copies HLA-DQB1*02 7 (44) 4 (40) 5 (36) 9 (17) 25 (27)
TG2 IgA‡ serology elevated 1 (6) 0 0 2 (4) 3 (3)
TG2 IgA‡ serology not done 2 (13) 4 (40) 2 (14) 0 8 (8)
Screening histology Marsh 0 or 1 †† 14 (88) 6 (60) ND ND  
TG2 IgA‡ negative & diagnosis ≥2 y 13 (81) 6 (60) 11 (79) 48 (91) 78 (84)
† Median (interquartile range). ‡TG2 IgA, INOVA rh transglutaminase 2 IgA. †† Modified Marsh score assessed by local pathologist on initial cuts of 
biopsies before re-cutting and quantitative histology was performed. GFD, gluten-free diet. ND, not done. 
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Table 2. Number (%) of patients with well-controlled coeliac disease (1O)†, and other 
coeliac disease patients, with indicated Marsh (M) grading based on quantitative 
histology of 2nd part duodenal biopsies. 
Study: 1 & 2 3 4 Total
Patients: 1O Other All 1O Other All 1O Other All 1O Other All
M0 0 0 0 1 (9) 0 1 (7) 0 0 0 1 (1) 0 1 (1)
M1 1 (5) 0 1 (4) 1 (9) 0 1 (7) 3 (6) 0 3 (6) 5 (6) 0 5 (5)
M2 5 (26) 1 (14) 6 (23) 3 (27) 0 3 (21) 19 (40) 2 (40) 21 (40) 27 (35) 3 (20) 30 (32)
M3a 12 (63) 6 (86) 18 (69) 6 (55) 2 (67) 8 (57) 25 (52) 2 (40) 27 (51) 43 (55) 10 (67) 53 (57)
M3b 1 (5) 0 1 (4) 0 1 (33) 1 (7) 1 (2) 1 (20) 2 (4) 2 (3) 2 (13) 4 (4)
M3c 0 0 0 0 0 0 0 0 0 0 0 0
Total 19 7 26 11 3 14 48 5 53 78 15 93
†Patients with TG2 IgA serology in the normal range and on gluten-free diet for >2 years are in the primary analysis population 
indicated by 1O, patients who had positive TG2 serology or it was positive, or were on GFD for <2 years are not in the primary 
analysis group are indicated by “Other”.
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Table 3. Number (%) of patients† with indicated Marsh (M) grading based on quantitative histology 
of 2nd part duodenal biopsies according to country of recruitment.
Location: Australia New Zealand USA
Study: 1&2 3 4 Total 1&2 4 Total 4 Total
M0 0 1 (9) 0 1 (3) 0 0 0 0 1 (1)
M1 0 1 (9) 2 (11) 3 (8) 1 (10) 1 (13) 2 (11) 0 5 (6)
M2 3 (33) 3 (27) 7 (37) 13 (33) 2 (20) 2 (25) 4 (22) 10 (48) 27 (35)
M3a 6 (67) 6 (55) 9 (47) 21 (54) 6 (60) 5 (63) 11 (61) 11 (52) 43 (55)
M3b 0 0 1 (5) 1 (3) 1 (10) 0 1 (6) 0 2 (3)
M3c 0 0 0 0 0 0 0 0 0
Total 9 11 19 39 10 8 18 21 78
†Limited to patients in the primary analysis population: TG2 IgA serology in the normal range and on gluten-free diet for >2 years
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Figure 1. A shows villous height to crypt depth ratios, and B shows intraepithelial 
lymphocyte (IEL) densities in formalin-fixed biopsies from the proximal and distal 
duodenum. Two biopsies were collected from the bulb, 1st, 2nd and 3rd part of the 
duodenum in 26 patients enrolled in the first and second phase 1 studies of Nexvax2. 
Medians and interquartile ranges are shown; p values by Wilcoxon test. Data for biopsies 
with well-oriented villus-crypt units is shown; data for biopsies from the bulb for two 
patients are missing as neither had any well-oriented villus-crypt units observed.
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Figure 2: A-F a series of hematoxylin eosin-stained cuttings of the same endoscopy 
forceps biopsy specimen fixed in PAXgene and embedded in paraffin. A shows the 
cutting that was graded as Marsh 1 because of tall normal looking villi and an increased 
density of intraepithelial lymphocytes. The hallmark for tangential cutting is evident, no 
crypts are cut longitudinally, only cross sections of crypts are seen. Morphometry cannot 
be performed, and neither can a Marsh class can be given. B shows a section from the A
cc
ep
te
d 
A
rt
ic
le
same biopsy block re-cut after tilting. C-F show four further sections resulting from 
further tilting between each re-cut. Crypt hyperplasia is evident and measurable villus-
crypt units in the 6 sections give a global mean villus height crypt depth ratio of 0.85, i.e 
Marsh class 3b according to Taavela et al. (16).
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Figure 3. Relationship between measurements of duodenal villus height and crypt 
depth, and their ratio or sum for the pooled set of 169 biopsy assessments from 93 
patients. A shows villus height and crypt depth are significantly, but weakly correlated, 
(Spearman correlation coefficient and associated P-value). B shows the individual sums 
of paired values of villus height and crypt depth measurements in each clinical trial for 
each site sampled. The median (interquartile range) for all 169 samples was 533 μm 
(482.5 - 575.5). No significant differences were found between biopsies from the 2nd 
part compared to biopsies from other sites in Study 1 and 2 (formalin-fixed), or 2nd part 
biopsies in Study 3 and 4 (PAXgene-fixed). C shows the expected strong correlations 
between villus height to crypt depth ratio and villus height, and to crypt depth. D shows 
villus height increases more about four-times more rapidly than crypt depth decreases 
as the sum of villus height and crypt depth increases (VH+CrD = 0.81*VH+273, and 
CrD = -019*VH+273). 
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Figure 4. Schematic representation of the relationship between villus height and crypt 
depth measurements in the duodenal mucosa of patients with treated coeliac disease in 
the present study. 
A
cc
ep
te
d 
A
rt
ic
le
